Back to results
US 2023/0348369 A1Published application
Nampt modulators
AssigneeCytokinetics, Inc.
InventorsAntonio ROMERO, Aroop CHANDRA, Christopher EVANS, Minxing SHEN
Life of this patent
Estimating the term…
Abstract
Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.
Claims104
A compound of Formula (II):
- or a pharmaceutically acceptable salt thereof,
- wherein:
- n is 0 to 6;
- Y1 is
- and R1 is selected from the group consisting of
- or
- Y1 is
- and R1 is selected from the group consisting of
- or
- Y1 is —C(O)—N(Rq)—(Rs), wherein Rq is H or C1-C6 alkyl, and Rs is C3-C8 cycloalkyl, optionally substituted C6-C14 aryl, optionally substituted 5- to 18-membered heteroaryl, or —(C1-C6 alkylene)-(optionally substituted C6-C14 aryl), and R1 is selected from the group consisting of
- or
- Y1 is —C(O)—Rb, wherein Rb is optionally substituted 3- to 18-membered heterocycloalkyl, and
- R1 is
- or
- Y1 is —N(Rt)—C(O)Ru, wherein Rt is H or C1-C6 alkyl, and Ru is optionally substituted C6-C14 aryl, optionally substituted 5- to 18-membered heteroaryl, or —(C1-C6 alkylene)-(5- to 18-membered heteroaryl), and R1 is
- or
- Y1 is
- and R1 is
- wherein
- R2a and R2b are each independently halo, —O(C1-C6 alkyl), C1-C6 alkyl substituted with —OH, —C(O)NR2cR2d, or —N(R2e)C(O)(C1-C6 alkyl);
- and
- R2c, R2d, and R2e are each independently hydrogen or C1-C6 alkyl;
- G1 is CH or N;
- p1 and p2 are each independently 0, 1, or 2;
- q1 and q2 are each independently 1 or 2;
- r is 1, 2, or 3;
- wherein, when Y1 is
- then n is 4, 5, or 6;
- when Y1 is
- and r is 1, then n is 2, 3, 4, 5, or 6;
- and
- when Y1 is —C(O)—N(Rq)—(Rs), —C(O)—Rb, —N(Rt)—C(O)Ru, or
- then n is 4 or 5;
- and
- R3 is selected from the group consisting of:
- i. unsubstituted C1-C6 alkyl;
- ii. C6-C14 aryl;
- iii. optionally substituted 5- to 18-membered heteroaryl;
- iv. —NR3aR3b, wherein
- R3a and R3b are each independently selected from the group consisting of hydrogen, C6-C14 aryl, 5- to 18-membered heteroaryl, —(C1-C6 alkylene)-(C6-C14 aryl), and —(C1-C6 alkylene)-(5- to 18-membered heteroaryl);
- v. —OR3c, wherein
- R3, is C6-C14 aryl, 5- to 18-membered heteroaryl, or —(C1-C6 alkylene)-(5- to 18-membered heteroaryl);
- vi. —C(O)R3d, wherein
- R3d is selected from the group consisting of —NR 3R3g;
- C3-C8 cycloalkyl;
- C3-C8 cycloalkyl substituted with optionally substituted C6-C14 aryl;
- C3-C8 cycloalkenyl;
- optionally substituted C6-C14 aryl;
- optionally substituted —(C1-C6 alkylene)-(C6-C14 aryl);
- optionally substituted 3- to 18-membered heterocycloalkyl;
- and optionally substituted 5- to 18-membered heteroaryl,
- wherein
- R3f and R3g are each independently selected from the group consisting of:
- (a) hydrogen,
- (b) optionally substituted C1-C6 alkyl,
- (c) C6-C14 aryl,
- (d) optionally substituted 3- to 18-membered heterocycloalkyl,
- (e) optionally substituted 5- to 18-membered heteroaryl,
- (f) optionally substituted C3-C10 cycloalkyl;
- and
- (g) optionally substituted C3-C10 cycloalkenyl;
- vii. C1-C6 alkyl substituted with one or more —OH, —C(O)NR3hR3i, optionally substituted C6-C14 aryl, optionally substituted 3- to 18-membered heterocycloalkyl, optionally substituted 5- to 18-membered heteroaryl, —N(R3p)—C(O)R3, —S(O)2—Rr, or —C(O)—Rs,
- wherein
- R3h and R3i are each independently selected from C1-C6 alkyl and —(C1-C6 alkylene)-(C6-C14 aryl),
- R3p is H or C1-C6 alkyl,
- R3q is C3-C8 cycloalkyl, optionally substituted 3- to 18-membered heterocycloalkyl, or optionally substituted 5- to 18-membered heteroaryl,
- R3r is C6-C14 aryl or 5- to 18-membered heteroaryl, and
- R3s is optionally substituted 3- to 18-membered heterocycloalkyl;
- viii. —C(O)OR3j, wherein
- R3j is hydrogen or C1-C6 alkyl;
- ix. —NHC(O)R3k, wherein
- R3k is optionally substituted C6-C14 aryl, optionally substituted —(C1-C6 alkylene)-(C6-C14 aryl), or optionally substituted 5- to 18-membered heteroaryl;
- x. —NHC(O)OR31, wherein
- R3l is hydrogen or C1-C6 alkyl;
- xi. —NHSO2R3m, wherein
- R3m is optionally substituted 5- to 18-membered heteroaryl, optionally substituted C6-C14 aryl, or —(C1-C6 alkylene)-(C6-C14 aryl), each of which is optionally substituted;
- and
- xii. —SO2R3n;
- wherein
- R3n is C1-C6 alkyl, optionally substituted C3-C10 cycloalkyl, optionally substituted C6-C14 aryl, or optionally substituted —(C1-C6 alkylene)-(C6-C14 aryl);
- R4 is phenyl or —C(O)NH—CH2-phenyl;
- R5′ and R5b are independently selected from the group consisting of hydrogen, methyl, and —NHC(O)O(C1-C6 alkyl);
- and
- R6 is selected from the group consisting of —C(O)OC(CH3)3, —NHC(O)O(C1-C6 alkyl), —C(O)-(optionally substituted phenyl), —C(O)—(C1-C6 alkylene)-(optionally substituted phenyl), —C(O)-(optionally substituted 3- to 18-membered heterocycloalkyl), —C(O)-(optionally substituted 5- to 18-membered heteroaryl), —C(O)—(C1-C6 alkylene)-(optionally substituted 5- to 18-membered heteroaryl), and 5- to 18-membered heteroaryl,
- provided that, when R6 is —C(O)-(substituted phenyl), —C(O)—(C1-C6 alkylene)-(optionally substituted phenyl), —C(O)-(optionally substituted 3- to 18-membered heterocycloalkyl), —C(O)-(optionally substituted 5- to 18-membered heteroaryl), —C(O)—(C1-C6alkylene)-(optionally substituted 5- to 18-membered heteroaryl), or 5- to 18-membered heteroaryl, then (1) n is 4 or 5, and (2) R1 is selected from the group consisting of
- wherein
- (1) when Y1 is
- and n is 0 or 1, then R1 is selected from the group consisting of
- and
- (2) when Y1 is
- and n is 0, then R1 is selected from the group consisting of
88 more elements
A compound selected from the group consisting of compounds of Table 1, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.